Molecular therapy for middle aged TIIDM patients: Verapamil, an anti-hyperglycemic medication, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 25/December/2017, 1.46 am

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; and Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA shows that “DNA-PK Promotes the Mitochondrial, […]

Combinatorial therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Matrine, Epicatechin, 14, 15, Epoxyeicosatrienoicacids (14, 15 EETs) (MEEET)  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 25/December/2017, 1.37 am

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA, shows that “Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of ß-adrenergic receptor signaling.” This study was published, in the 7 September 2017 issue […]

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Rosmarinic acid, isolated from Rosemary officinalis, and Perilla frutescens,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 24/December/2017, 11.51 pm

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost […]

Molecular therapy for Deafness: A therapeutic mix encompassing Moxonidine, Cholecalciferol, Ajoene and DIM (MOCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 24/December/2017, 11.43 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for Deafness: A therapeutic mix encompassing Moxonidine, Cholecalciferol, Ajoene and DIM (MOCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes [easy_payment currency=”USD”] From Significance […]

Molecular therapy for Diabetic retinopathy: Dimethyl Fumerate (DMF) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 24/December/2017, 1.10 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner site Rhein-Main, Germany shows that “Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy.” This research paper was published, in the 6 December 2017 issue of […]

Molecular therapy for TIIDM and obesity-associated metabolic deficits: A pharmaceutical mixture (PMSFN) encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 24/December/2017, 1.01 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” This research paper, was published in the 8 March 2017 issue of the journal “Nature” [One of the best research journals […]